SecBot SecBot
Insider Cluster (2 insiders) ·Filed Apr 1, 2026

SYRE

Spyre Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $703K total
Actionable Insight ▼ Bearish

While the dollar amount is not large relative to market cap, the coordinated exit by two top executives immediately after exercising options may signal lack of near-term conviction. Traders should monitor for absence of offsetting buys and watch for upcoming earnings or clinical updates that could explain timing.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$48.90
T+0 close · Mar 31, 2026 · via day close
Latest settled
+84.38%
T+60 · $90.16
Vs SPY
+71.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $48.90entry
  2. T+1 · 8mo ago −2.70%α −2.78% · $47.58
  3. T+5 · 7mo ago +5.87%α +2.10% · $51.77
  4. T+20 · 7mo ago +47.01%α +37.29% · $71.89
  5. T+60 · 5mo ago +84.38%α +71.00% · $90.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two key executives at Spyre Therapeutics, the CFO and CMO, sold a combined $703K in open-market transactions on April 1, 2026, following derivative exercises. The sales represent a modest but notable insider selling cluster involving C-suite leadership.

Key Financial Metrics

Direction
selling
Total Value
$703.0K
Insiders
2

Key Facts

  • CFO Burrows Scott L sold 6,200 shares for $305,102 at $49.21 per share.
  • CMO Sloan Sheldon sold 7,958 shares for $397,900 at $50.00 per share.
  • Both executives also exercised in-the-money derivatives prior to selling, with no additional open-market purchases.
  • Total open-market sale value: $703K, representing ~0.019% of $3.7B market cap, modest in size but significant due to C-suite participation.
  • No insider buying was reported in the cluster.

Financial Impact

$703,000 in net insider selling by CFO and CMO

insider sentimentshareholder confidence

Risk Factors

  • Perception of insider pessimism given no reinvestment or retention of shares post-exercise.
  • Potential for negative market reaction due to C-suite selling, especially if no clear rationale is disclosed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SYRE-1775266236001

Track record

36 reports on SYRE

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026